Teladoc Health heads into its July 28 earnings date with a striking disconnect: the stock has rallied 35% in a month, yet short sellers are adding, not leaving.
The most interesting development this week came from the Street. Bank of America's healthcare analyst raised his price target on TDOC to $10.50 from $9.00 on July 7, maintaining a Buy rating — the freshest bullish signal the stock has received in months. That move matters because it arrives just as the stock broke back above $9.50, crossing the prior BofA target for the first time. The broader analyst picture is more mixed. Citi holds Neutral with a $7.00 target, Evercore sits at In-Line, and JPMorgan has Neutral at $7.00 after cutting from $9.00 in March. The mean target of $7.68 sits below the current price of $9.52, which means the stock has, for now, outrun the consensus. Deutsche Bank is the outlier on the upside, carrying a $11.00 Buy initiated in March. Bulls point to Teladoc's whole-person virtual care platform and an improving cash flow trajectory. Bears flag BetterHelp segment headwinds, near-term EBITDA estimate cuts, and execution risk on margin expansion. The EV/EBITDA multiple of 5.8x has drifted higher over the past 30 days in line with the price recovery, though the EPS momentum factor scores rank near the bottom of the universe — 16th percentile on 30-day momentum, 10th on 90-day — a reminder that estimate revisions haven't followed the stock's move.
Short positioning tells a more cautious story than the price action alone would suggest. Short interest is elevated at nearly 17% of the free float — roughly 30 million shares — and has climbed about 14% over the past month, even as the stock ran higher. That's a notable divergence: the rally has not been driven by short covering. Days to cover remain extended at 7.4, and the ORTEX short score of 66 places TDOC in the upper third of the market for short-side pressure. Where the lending picture is less charged is in borrow conditions. Availability runs at 306% — meaning there are roughly three shares available to borrow for every one already lent out — comfortably above the 52-week floor of 190%. Cost to borrow is just 0.44%, barely above its recent range. The lending market is not signalling a squeeze setup; new shorts can access supply cheaply and easily. Positioning looks elevated but not combustible.
Options traders are decisively bullish in tone, adding texture to the week's move. The put/call ratio dropped to 0.38 on July 7 — more than three standard deviations below its 20-day average of 0.41. That's an unusually lopsided call-heavy lean, near the lower end of the 52-week range of 0.28 to 1.03. Call positioning of that magnitude, in the context of a stock up 12% in a week and with earnings three weeks away, suggests a cohort of investors is positioning for further upside rather than hedging.
The institutional ownership picture has a few notable threads. Voss Capital reported a position of 8.3 million shares as of June 17, having added 4.1 million shares — a material increase by a specialist active manager. BlackRock added roughly 509,000 shares as of June 30. Point72 carried 7.7 million shares at March quarter-end. That active-manager accumulation stands in contrast to recent insider activity, which has been consistently on the sell side. Division president Kelly Bliss sold 7,500 shares across three transactions between June 29 and July 6, averaging prices between $8.50 and $9.50. The CEO received stock awards in June and promptly sold a portion. None of the values are large enough to signal distress, but the direction of insider flow does not corroborate the call-heavy options skew.
The earnings history offers a useful reference point. The last Q1 print on May 21 produced a 1.4% next-day move and a 16% five-day gain. The prior event similarly produced a modest day-one reaction followed by a 13% five-day move. The pattern — muted next-day, meaningful follow-through — suggests the market has tended to need a few days to process Teladoc results. Q2 results on July 28 will therefore be worth watching not just for the initial reaction, but for how the stock trades in the week that follows, particularly given how far price has run ahead of the analyst consensus going in.
See the live data behind this article on ORTEX.
Open TDOC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
